Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide and serum inflammatory cytokines in postmenopausal osteoporosis
ChiCTR1800018858Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teriparatide in postmenopausal osteoporosis, sponsored by Tianjin Medical University General Hospital. Primary endpoint: Serum inflammatory cytokines at 3 months. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
teriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on ChiCTR1800018858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018858.